Ampersand Medical Presents Better Alternative for Pap Test Collection Device

Study Reveals InPath e2 Collector Increases Adequate Cervical Sampling



Apr 30, 2001, 01:00 ET from Ampersand Medical Corp.

    CHICAGO, April 30 /PRNewswire/ -- Ampersand Medical Corp.
 (OTC Bulletin Board:   AMPM), recognizing that abnormal cells often aren't found
 in Pap tests because they never make it to the examining slide, is previewing
 the industry's forthcoming alternative to spatula and brush methods of
 collecting cervical cells.
     Early data about the new device is being presented during the 50th Annual
 Meeting of the American College of Obstetricians and Gynecologists (ACOG) in
 Chicago, April 28 - May 1.
     A pilot study presented at ACOG indicates that the InPath(TM) e2
 Collector, a new balloon device for collecting cervical cells, offers the
 potential for more accurate Pap testing by increasing the likelihood of
 improved sample adequacy.  The study which is on-going as part of a clinical
 trial for a future FDA submission, conducted at University Hospitals of
 Cleveland, compared samples obtained by the InPath e2 Collector with those
 collected though use of the commonly used brush or spatula.
     George Gorodeski, MD PhD, associate professor of reproductive biology at
 Case Western Reserve University in Cleveland and lead investigator in the in
 the study, said that participating physicians reported the new device was
 easier to use than the conventional method.  In addition, the majority of
 patients reported the sampling procedure was more comfortable with the InPath
 e2 Collector than with conventional collection techniques.
     "We were impressed with the preliminary performance of the InPath e2
 Collector," said Dr. Gorodeski.  "Our study demonstrated that the accuracy of
 cytology reports retrieved with this device were better than those obtained
 with the conventional brush/spatula.  This, in conjunction with improved
 sampling of the cervix and women having to return for re-testing, should
 ultimately reduce the issues of inconvenience and fear.  It has thus far also
 provided a more comfortable and shorter examination for the patient and an
 easier procedure for the physician."
     The e2 Collector is based on use of a proprietary balloon in the shape of
 a mirror image of the cervix.  When it is inflated in the cervix, cells adhere
 to its surface.  This allows cells to be easily obtained from the entire
 cervix and is much less dependent on the efficacy of user technique than are
 current methods.
     "We know that not all physicians successfully capture all the cells that
 should be studied for a Pap test," said Eric Gombrich, vice president of
 Ampersand Medical, which developed the new collection device.   "This first
 study using the e2 Collector demonstrates that the device may assure an
 improved level of care, at the same time that it saves time for physicians and
 lessens discomfort for patients."
 
     About Ampersand Medical
     Ampersand Medical Corporation develops cost-effective, laboratory-based
 and point-of-care screening systems to assist in the early detection of
 cervical and other cancers.  The InPath(TM) System is being developed to
 provide medical practitioners with a highly accurate, low-cost, cervical
 cancer screening system that can be used at the point-of-care.  Other products
 include AIM 2000, an automated system facilitating the analysis of medical
 samples and SAMBA(TM) Virtual Laboratory software used for medical image
 processing, database and multimedia case management, telepathology and
 teleradiology.  More information is available on the Internet at
 http://www.ampersandmedical.com .
 
     Certain statements throughout this release are forward-looking. These
 statements are based on the Company's current expectations and involve many
 risks and uncertainties, such as the possibility that clinical trials will not
 substantiate the Company's expectations with respect to the InPath(TM) System,
 and other factors set forth in reports and documents filed by Ampersand
 Medical Corporation with the Securities and Exchange Commission.  Ampersand
 Medical Corporation undertakes no obligation to publicly update or revise any
 forward-looking statements contained herein.
 
     CONTACT:  Media, Gail Cowan, 312-832-9300, ext. 212, or Investors,
 Kristin Anderson, 312-832-9300, ext. 256, both of Corporate Technology
 Communications for Ampersand Medical.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X21367437
 
 

SOURCE Ampersand Medical Corp.
    CHICAGO, April 30 /PRNewswire/ -- Ampersand Medical Corp.
 (OTC Bulletin Board:   AMPM), recognizing that abnormal cells often aren't found
 in Pap tests because they never make it to the examining slide, is previewing
 the industry's forthcoming alternative to spatula and brush methods of
 collecting cervical cells.
     Early data about the new device is being presented during the 50th Annual
 Meeting of the American College of Obstetricians and Gynecologists (ACOG) in
 Chicago, April 28 - May 1.
     A pilot study presented at ACOG indicates that the InPath(TM) e2
 Collector, a new balloon device for collecting cervical cells, offers the
 potential for more accurate Pap testing by increasing the likelihood of
 improved sample adequacy.  The study which is on-going as part of a clinical
 trial for a future FDA submission, conducted at University Hospitals of
 Cleveland, compared samples obtained by the InPath e2 Collector with those
 collected though use of the commonly used brush or spatula.
     George Gorodeski, MD PhD, associate professor of reproductive biology at
 Case Western Reserve University in Cleveland and lead investigator in the in
 the study, said that participating physicians reported the new device was
 easier to use than the conventional method.  In addition, the majority of
 patients reported the sampling procedure was more comfortable with the InPath
 e2 Collector than with conventional collection techniques.
     "We were impressed with the preliminary performance of the InPath e2
 Collector," said Dr. Gorodeski.  "Our study demonstrated that the accuracy of
 cytology reports retrieved with this device were better than those obtained
 with the conventional brush/spatula.  This, in conjunction with improved
 sampling of the cervix and women having to return for re-testing, should
 ultimately reduce the issues of inconvenience and fear.  It has thus far also
 provided a more comfortable and shorter examination for the patient and an
 easier procedure for the physician."
     The e2 Collector is based on use of a proprietary balloon in the shape of
 a mirror image of the cervix.  When it is inflated in the cervix, cells adhere
 to its surface.  This allows cells to be easily obtained from the entire
 cervix and is much less dependent on the efficacy of user technique than are
 current methods.
     "We know that not all physicians successfully capture all the cells that
 should be studied for a Pap test," said Eric Gombrich, vice president of
 Ampersand Medical, which developed the new collection device.   "This first
 study using the e2 Collector demonstrates that the device may assure an
 improved level of care, at the same time that it saves time for physicians and
 lessens discomfort for patients."
 
     About Ampersand Medical
     Ampersand Medical Corporation develops cost-effective, laboratory-based
 and point-of-care screening systems to assist in the early detection of
 cervical and other cancers.  The InPath(TM) System is being developed to
 provide medical practitioners with a highly accurate, low-cost, cervical
 cancer screening system that can be used at the point-of-care.  Other products
 include AIM 2000, an automated system facilitating the analysis of medical
 samples and SAMBA(TM) Virtual Laboratory software used for medical image
 processing, database and multimedia case management, telepathology and
 teleradiology.  More information is available on the Internet at
 http://www.ampersandmedical.com .
 
     Certain statements throughout this release are forward-looking. These
 statements are based on the Company's current expectations and involve many
 risks and uncertainties, such as the possibility that clinical trials will not
 substantiate the Company's expectations with respect to the InPath(TM) System,
 and other factors set forth in reports and documents filed by Ampersand
 Medical Corporation with the Securities and Exchange Commission.  Ampersand
 Medical Corporation undertakes no obligation to publicly update or revise any
 forward-looking statements contained herein.
 
     CONTACT:  Media, Gail Cowan, 312-832-9300, ext. 212, or Investors,
 Kristin Anderson, 312-832-9300, ext. 256, both of Corporate Technology
 Communications for Ampersand Medical.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X21367437
 
 SOURCE  Ampersand Medical Corp.